Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 5, 1998, Pages 1619-1623

  Katznelson, Laurence ^a   Bogan, Jonathan S ^a   Trob, Joshua R ^a   Schoenfeld, David A ^a   Hedley Whyte, E Tessa ^a   Hsu, Dora W ^a   Zervas, Nicholas T ^a   Swearingen, Brooke ^a   Sleeper, Maxine ^a   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; HYDROCORTISONE; HYDROXYCORTICOSTEROID; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ANTIBODY LABELING; ARTICLE; CLINICAL FEATURE; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; CUSHING SYNDROME; DEXAMETHASONE SUPPRESSION TEST; FEMALE; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKULL RADIOGRAPHY; TUMOR VOLUME;

17-HYDROXYCORTICOSTEROIDS; ADENOMA; ADRENOCORTICOTROPIC HORMONE; ADULT; CUSHING SYNDROME; DEXAMETHASONE; FEMALE; HUMANS; HYDROCORTISONE; KI-67 ANTIGEN; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; REFERENCE VALUES; RETROSPECTIVE STUDIES;

EID: 7844222086     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.5.1619     Document Type: Article

References (22)

1. Kaye TB, Crapo L. 1990 The Cushing's syndrome: an update on diagnostic tests. Ann Intern Med. 112:434-444.
2. Tsigos C, Chrousos GP. 1996 Differential diagnosis and management of Cushing's syndrome. Annu Rev Med. 47:443-461.
3. Biller BM. 1994 Pathogenesis of pituitary Cushing's syndrome. Pituitary vs. hypothalamic [Review]. Endocrinol Metab Clin North Am. 23:547-554.
4. Robert F, Hardy J, 1991 Cushing's disease: a correlation of radiological, surgical and pathological findings with therapeutic results. Pathol Res Pract. 187:617-621.
5. Gibson S, Ray DW, Crosby SR, et al. 1996 Impaired processing of proopiomelanocortin in corticotroph macroadenomas. J Clin Endocrinol Metab. 81:497-502.
6. Aron DC, Findling JW, Fitzgerald PA, Forsham PH, Wilson CB, Tyrrell JB. 1982 Cushing's syndrome: problems in management. Endocr Rev. 3:229-244.
7. Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET. 1997 Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol. 56:857-865.
8. Salassa RM, Kearns TP, Kernohan JW, Sprague RG, MacCarty CS. 1959 Pituitary tumors in patients with Cushing's syndrome. J Clin Endocrinol Metab. 19:1523-1539.
9. Klibanski A, Zervas NT. 1991 Diagnosis and management of hormone-secreting pituitary adenomas. N Engl J Med. 324:822-831.
10. Katznelson L, Alexander JM, Klibanski A. 1993 Clinical review 45: clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 76:1089-1094.
11. Flack MR, Oldfield EH, Cutler GB, et al. 1992 Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome. Ann Intern Med. 116:211-217.
12. Biller BM, Alexander JM, Zervas NT, Hedley-Whyte ET, Arnold A, Klibanski A. 1992 Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. J Clin Endocrinol Metab. 75:1303-1309.
13. Gicquel C, Bouc YL, Luton JP, Girard F, Bertagna X. 1992 Monoclonality of corticotroph macroadenomas in Cushing's disease. J Clin Endocrinol Metab. 75:472-475.
14. Gaitan D, DeBold CR, Tumey MK, Zhou P, Orth DN, Kovacs WJ. 1995 Glucocorticoid receptor structure and function in an adrenocorticotropin-secreting small cell lung cancer. Mol Endocrinol. 9:1193-1201.
15. Karl M, Von Wichert G, Kempter E, et al. 1996 Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab. 81:124-129.
16. Malchoff DM, Brufsky A, Reardon G, et al. 1993 A mutation of the glucocorticoid receptor in primary Cortisol resistance. J Clin Invest. 91:1918-1925.
17. Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, Stein H. 1984 Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133:1710-1715.
18. Hall PA, Crocker J, Watts A, Stansfeld AG. 1988 A comparison of nucleolar organizer region staining and Ki-67 immunostaining in non-Hodgkin's lymphoma. Histopathology. 12:373-381.
19. Thapar K, Kovacs K, Scheithauer BW, et al. 1996 Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 38:99-106.
20. Shibuya M, Saito F, Miwa T, Davis RL, Wilson CB, Hoshino T. 1992 Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol (Berl). 84:178-183.
21. Knosp E, Kitz K, Perneczky A. 1989 Proliferation activity in pitutiary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery. 25:927-930.
22. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. 1997 Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 82:2102-2107.